- Title
- TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients with Metastatic Urothelial Cancer Progressing after Previous Checkpoint Inhibitor Therapy
- Creators
- Daniel P. Petrylak - Yale UniversityScott T. Tagawa - Cornell UniversityRohit K. Jain - Moffitt Cancer CenterManojkumar Bupathi - Rocky Mountain Cancer CentersArjun Balar - NYU Langone HealthArash Rezazadeh Kalebasty - University of California, IrvineSaby George - Roswell Park Comprehensive Cancer CenterPhillip Palmbos - University of MichiganLuke Nordquist - Urology Cancer Center, Omaha, NE, United StatesNancy Davis - Vanderbilt UniversityChethan Ramamurthy - The University of Texas Health Science Center at San AntonioCora N. Sternberg - Cornell UniversityYohann Loriot - Université Paris-SaclayNeeraj Agarwal - Huntsman Cancer InstituteChandler Park - Norton HealthcareJulia Tonelli - Reckitt Benckiser (United States)Morganna Vance - Reckitt Benckiser (United States)Huafeng Zhou - Reckitt Benckiser (United States)Petros Grivas - University of Washington
- Publication Details
- Journal of clinical oncology, Vol.42(29), pp.3410-3420
- Number of pages
- 11
- Grant note
- Gilead Sciences (http://data.elsevier.com/vocabulary/SciValFunders/100005564)
- Identifiers
- 991006262547202656
- Academic Unit
- Radiology
- Language
- English
- Resource Type
- Journal article
Journal article
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients with Metastatic Urothelial Cancer Progressing after Previous Checkpoint Inhibitor Therapy
Journal of clinical oncology, Vol.42(29), pp.3410-3420
10/10/2024
PMID: 39186707
Metrics
1 Record Views